When viewed alongside satiety and glucose homeostatic actions, this suggests that GLP-2 has untapped potential for the treatment of diabetes and obesity, either alone or perhaps more likely alongside GLP-1 therapies. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.